{"analyses":[{"ciLowerLimit":"0.59","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.98","estimateComment":"Stratifying variables were fixed covariates: prior hormone therapy (yes/no), entry prostate-specific antigen (PSA) (1.6-4.0 vs. 0.2-1.5), PSA nadir after surgery (\\< 0.5 vs. \\>= 0.5), positive surgical margins (yes/no). Reference level = placebo arm.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.020","pValueComment":"One-sided significance level = 0.046 to preserve overall significance level of 0.05 for the study.","paramType":"Hazard Ratio (HR)","paramValue":"0.77","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"66.5","upperLimit":"76.0","value":"71.3"},{"groupId":"OG001","lowerLimit":"71.9","upperLimit":"80.8","value":"76.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"394"},{"groupId":"OG001","value":"376"}],"units":"Participants"}],"description":"Overall survival rates were estimated by the Kaplan-Meier method, with failure defined as death by any cause. Four-year follow-up was required of all patients, twelve-year rates are reported. Four-year follow-up was required of all patients, but twelve-year rates were reported.\n\nPatients are followed until death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy (64.8 Gy) + placebo (daily 2 years)","id":"OG000","title":"Placebo"},{"description":"Radiation therapy (64.8 Gy) + bicalutamide (150 mg daily 2 years)","id":"OG001","title":"Bicalutamide"}],"paramType":"NUMBER","populationDescription":"Eligible patients who did not withdraw consent.","reportingStatus":"POSTED","timeFrame":"From date of randomization to 12 years.","title":"Overall Survival (12-year Rates Reported)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}